Aurobindo Pharma Receives USFDA Final Approval for Perampanel Tablets in Six Strengths
Hyderabad-headquartered Aurobindo Pharma Limited has announced receipt of final approval from the US Food & Drug Administration (USFDA) for Perampanel Tablets, covering six dosage strengths: 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. The approved product is bioequivalent and therapeutically equivalent to Catalyst Pharmaceuticals' Fycompa® Tablets.